A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
Clinical Trial Grant
Administered By
Pediatrics, Transplant and Cellular Therapy
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 1, 2015
End Date
March 23, 2022
Administered By
Pediatrics, Transplant and Cellular Therapy
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 1, 2015
End Date
March 23, 2022